Vivo Bio Tech Ltd
BSE:511509
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
26.4
45.21
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| IN |
V
|
Vivo Bio Tech Ltd
BSE:511509
|
583.9m INR |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
972.2B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.5B USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
393.1B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
277.1B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.4B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
219B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.1B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
Market Distribution
| Min | -305 007.7% |
| 30th Percentile | 2.1% |
| Median | 5.8% |
| 70th Percentile | 11.6% |
| Max | 1 221 633.3% |
Other Profitability Ratios
Vivo Bio Tech Ltd
Glance View
Vivo Bio Tech Ltd. engages in the provision of drug development and discovery services. The company is headquartered in Hyderabad, Telangana. The firm provides services of in-vitro, in-vivo, toxicity studies, pharmacological investigations, pharmacokinetic and toxicokinetic studies. The firm's services are offered to pharma, biotech and Agri companies, which include molecular biology services, the fermentation process of E.Coli harboring the plasmid containing the gene of interest, protein purification, bioassay, Physico-chemical and biochemical/immunological characterization of various proteins. The firm's In-vivo services provide preclinical testing services in rodents/non-rodents, and canines. The firm's subsidiaries include Vivobio Labs Private Ltd, Vivobio Discovery services Private Ltd, Surlogic Life Consultancy Private Ltd and Vivobio Consulting Services Private Ltd.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Vivo Bio Tech Ltd is 8.2%, which is below its 3-year median of 8.9%.
Over the last 3 years, Vivo Bio Tech Ltd’s Net Margin has increased from 2.2% to 8.2%. During this period, it reached a low of -0.2% on Dec 31, 2022 and a high of 17.2% on Jun 30, 2025.